Background
Reducing the effectiveness of broad-spectrum cephalosporins against
Enterobacteriaceae
infections has been recognized. This study aimed to investigate risk factors and clinical significance of third-generation cephalosporin nonsusceptibility (3GC-NS) among the cases of monomicrobial
Enterobacteriaceae
bacteremia (mEB) at regional or district hospitals.
Methods
The study was conducted at three hospitals in southern Taiwan between Jan. 2017 and Oct. 2019. Only the first episode of mEB from each adult (aged ≥20 years) was included. The primary outcome was in-hospital crude mortality.
Results
Overall there were 499 episodes of adults with mEB included, and their mean age was 74.5 years. Female predominated, accounting for 53% of all patients.
Escherichia coli
(62%) and
Klebsiella pneumoniae
(21%) were two major causative species. The overall mortality rate was 15% (73/499), and patients infected by 3GC-NS isolates (34%, 172/499) had a higher mortality rate than those by 3GC-susceptible isolates (66%, 327/499) (21% vs 11%,
P
=0.005). By the multivariate analysis, 3GC-NS was the only independent prognostic determinant (adjusted odds ratio [AOR], 1.78;
P
=0.04). Of note, male (AOR 2.02,
P
=0.001), nosocomial-acquired bacteremia (AOR 2.77,
P
<0.001), and usage of nasogastric tube (AOR 2.01,
P
=0.002) were positively associated with 3GC-NS, but
P. mirabilis
bacteremia (AOR 0.28,
P
=0.01) and age (AOR 0.98,
P
=0.04) negatively with 3GC-NS.
Conclusion
For adults with
Enterobacteriaceae
bacteremia, 3GC-NS signifies a significant prognostic impact. Efforts to rapid identification of such antimicrobial resistance profiles should be incorporated into antimicrobial stewardship programs to achieve favorable outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.